Condition (MeSH)
Necrobiotic Disorders
ClinicalTrials.gov lists 15 trials for Necrobiotic Disorders or a narrower condition beneath it. Processa Pharmaceuticals has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Necrobiotic Disorders trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2014 | 1 |
| 2008 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Necrobiotic Disorders trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 4 |
How many Necrobiotic Disorders trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 10 |
| Terminated | 3 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Necrobiotic Disorders trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Processa Pharmaceuticals | 2 |
| AI Labs Group S.L | 1 |
| Istanbul Training and Research Hospital | 1 |
| TWi Biotechnology, Inc. | 1 |
Which drugs are being tested for Necrobiotic Disorders? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| CTP-499 | 2 |
| Abrocitinib | 1 |
| (CP-6890,550) Tofacitinib | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ruxolitinib IR | 1 |
| AC-1101 | 1 |
| Secukinmab | 1 |
| Corticosteroid with lidocaine | 1 |
| Deucravacitinb | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Necrobiotic Disorders? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Panniculitis. Part I. Mostly septal panniculitis. | Journal of the American Academy of Dermatology | 2001 | No |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.